Odonate Therapeutics (ODT) PT Raised to $11 at Goldman Sachs, Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ODT Hot Sheet
Price: $1.12 --0%
Rating Summary:
0 Buy, 2 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
0 Buy, 2 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi raised the price target on Odonate Therapeutics (NASDAQ: ODT) to $11.00 (from $10.00) while maintaining a Sell rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Downgrades RPC Inc. (RES) to Sell
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Citi raises General Dynamics price target to $400, keeps Neutral
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman Sachs, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
